An Observational, Multicenter Study to Evaluate the Use and Effectiveness of Doptelet® in Patients With ITP
← catalyst calendarSponsored by Swedish Orphan Biovitrum (industry) · SOBI.ST — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
199actual
Sites
55
Countries
Croatia, Czechia, Germany +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-02-22 | actual | When the study began enrolling |
| Primary completion | 2025-06-10 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-10 | actual | The whole study's end, after follow-up |
| First posted | 2021-06-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Immune Thrombocytopenia
- ITP
Intervention
- Drug: Avatrombopag — also filed as Doptelet®
Primary outcome
what the primary-completion date above is the date OFCumulative number of weeks with a platelet count ≥30×109/L during Doptelet treatment.
measured Data will be collected for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Permalink · SOBI.ST's whole pipeline · Catalyst calendar · Every registered study · What changed